Short Read Sequencing Market Report 2026

Short Read Sequencing Market Overview

• Short Read Sequencing market size has reached to $7.8 billion in 2025 • Expected to grow to $17.75 billion in 2030 at a compound annual growth rate (CAGR) of 17.9% • Growth Driver: Short Read Sequencing Market Thrives On The Soaring Adoption Of Personalized Medicine • Market Trend: Hybrid Sequencing Breakthrough Expands Genomic Insight With Integrated Long-Read Capability • North America was the largest region in 2025 and Asia-Pacific is the fastest growing region.

What Is Covered Under Short Read Sequencing Market?

Short-read sequencing, or next-generation sequencing (NGS), is a high-throughput DNA sequencing method that generates short fragments or reads of DNA sequences. It revolutionized genomics by enabling the rapid and cost-effective analysis of entire genomes and transcriptomes. The main product types of short read sequencing are instruments, consumables, and services. Short-read sequencing instruments refer to the sequencing platforms or machines used to generate short DNA fragments for analysis, enabling the identification of genetic variations, mutations, and gene expression levels. The various technologies include next-generation sequencing, sanger sequencing and various workflows including pre-sequencing, sequencing, and data analysis that are applied in clinical investigation, oncology, reproductive health, consumer genomics, agri genomics and forensics, HLA typing or immune system monitoring. The end users of short-read sequencing include academic research, hospital, and clinics, clinical research, and pharmaceutical and biotechnology companies.

What Is The Short Read Sequencing Market Growth Forecast?

The short read sequencing market size is expected to see rapid growth in the next few years. It will grow to $17.75 billion in 2030 at a compound annual growth rate (CAGR) of 17.9%. The growth in the forecast period can be attributed to increasing adoption of precision medicine programs, rising demand for oncology and rare disease sequencing, expansion of clinical diagnostics using NGS, growing investments in genomics data infrastructure, increasing use of AI-driven sequence analysis. Major trends in the forecast period include increasing adoption of high-throughput sequencing platforms, rising demand for cost-effective whole genome sequencing, growing integration of advanced bioinformatics pipelines, expansion of clinical and translational genomics applications, enhanced focus on sequencing accuracy and speed.

Global Short Read Sequencing Market Segmentation

1) By Product: Instruments, Consumables, Services 2) By Workflow: Pre-Sequencing, Sequencing, Data Analysis 3) By Application: Clinical Investigation, Oncology, Reproductive Health, Consumer Genomics, Agri genomics And Forensics, HLA Typing Or Immune System Monitoring 4) By End Users: Academic Research, Hospitals And Clinics, Clinical Research, Pharmaceutical And Biotechnology Companies Subsegments: 1) By Instruments: Next-Generation Sequencing (NGS) Systems, Sequencing Platforms, Library Preparation Systems 2) By Consumables: Reagents And Kits, Flow Cells, Sample Preparation Consumables 3) By Services: Sequencing Services, Data Analysis Services, Bioinformatics Services

What Is The Driver Of The Short Read Sequencing Market?

The rising adoption of personalized medicine is significantly contributing to the growth of short read sequencing market going forward. Personalized medicine tailors’ medical treatment to an individual's unique genetic makeup, offering more effective and precise healthcare interventions. Short read sequencing plays a pivotal role in identifying genetic variations that influence drug response, enabling the development of personalized treatment plans. For instance, in February 2024, according to the Personalized Medicine Coalition, a US-based nonprofit organization, the USFDA approved 16 new personalized treatments for rare disease patients in 2023, a significant increase from 6 personalized treatments in 2022. Therefore, the rising adoption of personalized medicine will drive the short-read sequencing market.

Key Players In The Global Short Read Sequencing Market

Major companies operating in the short read sequencing market are F. Hoffmann-La Roche AG, Thermo Fisher Scientific Inc., Illumina Inc., Agilent Technologies Inc., QIAGEN N.V., PerkinElmer Inc., Eurofins Scientific SE, BGI Genomics Co Ltd, MGI Tech Co. Ltd., 10x Genomics Inc., Zymo Research Corporation, Paragon Genomics Inc., Novogene Co. Ltd, Macrogen Inc., Fasteris SA, GenScript Biotech Corporation, Element Biosciences Inc., Singular Genomics Systems Inc., Ultima Genomics Inc., GenapSys Inc.

Global Short Read Sequencing Market Trends and Insights

Major companies operating in the short-read sequencing market are focusing on developing innovative advancements such as hybrid long-/short-read sequencing assays to expand analytical capabilities and improve access to complex genomic regions. A hybrid long-/short-read sequencing assay is a workflow that enables the generation of both long and short sequencing reads on a single platform, providing enhanced genomic resolution while maintaining compatibility with standard high-throughput sequencing systems. For instance, in March 2023, Illumina Inc., a US-based provider of DNA sequencing and array-based technologies, launched the Illumina Complete Long Read Prep, Human assay. The product integrates long-read capability into existing short-read sequencing instruments, allowing laboratories to obtain comprehensive genomic data without adopting separate long-read systems. It also supports low DNA input requirements and delivers high accuracy, thereby improving the ability to analyze difficult-to-map genomic regions while reducing workflow complexity.

What Are Latest Mergers And Acquisitions In The Short Read Sequencing Market?

In March 2023, QIAGEN N.V., a German-based provider of sample and assay technologies including short read sequencing partnered with Sophia Genetics SA. With this partnership, QIAGEN N.V. at enhancing next-generation sequencing (NGS) capabilities with its QIAseq reagent technology and SOPHiA's DDM (Digital Data Management) platform, allowing for improved tumor analysis and somatic variant detection. Sophia Genetics SA is a Switzerland-based medicine software company.

Regional Outlook

North America was the largest region in the Short Read Sequencing market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in this market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in this market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain

What Defines the Short Read Sequencing Market?

The short-read sequencing market includes revenues earned by entities by providing short-read sequencing services such as sequencing services, bioinformatics, sample processing, sequencing runs, data generation, and analysis. The market value includes the value of related goods sold by the service provider or included within the service offering. The short-read sequencing market also consists of sales-related products such as sequencing instruments, reagents, and consumables. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

How is Market Value Defined and Measured?

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.